Avelumab, durvalumab and atezolizumab inhibit binding of T cells to PDL-1 on the tumor surface and ipilimumab, among others, targets cytotoxic T lymphocyte-associated antigen-4 (CTLA-4) [13]. This evidence concerns the gene CTLA4 and neoplasm.